DexCom (DXCM) Q3 FY2026 Earnings Call: Guidance and Outlook
Management updated full year 2026 revenue guidance while maintaining gross margin expectations and raising operating and EBITDA margin targets.
About DexCom. DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners.
No specific formal quarterly guidance range was provided for the fourth quarter, though the annual guidance implies fourth quarter midpoint growth of 10%.
Annual guidance
Revenue
$5.20 billion to $5.25 billion, representing growth of 12% to 13%.
Gross Profit Margin
Approximately 64% on a non-GAAP basis.
Operating Profit Margin
Approximately 24% on a non-GAAP basis.
Adjusted EBITDA Margin
Approximately 32%.
Outlook
Category demand
Active base growth remains strong in the upper teens with stable low double-digit category growth.
International normalization
International revenue growth of 5% reflects lapping of prior year reimbursement wins, with normalization expected at the start of next year.
Manufacturing scale
The Ireland facility initiated commercial production on schedule, expanding global manufacturing capacity across the U.S., Europe, and Asia Pacific.
Capital deployment
The company completed $1 billion in share repurchases for 2026 and announced another $1 billion share repurchase authorization for 2027.
Dombey's summary of the DexCom Q3 FY2026 earnings call held Oct 29, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
